Summary
The apparent antipsychotic action of the selective 5-HT2a receptor antagonist M100907 in MK-801-treated NMRI mice was shown to be markedly counteracted by the 5-HT2a/2c receptor antagonist ritanserin. The mechanism of action and potential implications are discussed.
Similar content being viewed by others
References
Baxter G, Kennett G, Blaney F, Blackburn T (1995) 5-HT2 receptor subtypes: a family reunited? Trends Pharmacol Sci 16: 105–10
Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1990) 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13: 500–6
Bunney BG, Bunney WE, Carlsson A (1995) Schizophrenia and glutamate. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 1205–1215
Carlsson ML (1995) The selective 5-HT2a-receptor antagonist MDL100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse implications for psychosis. J Neural Transm [Gen Sect] 100: 225–237
Devaud LL, Hollingsworth EB, Cooper BR (1992) Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin2 receptor antagonist, ritanserin. J Neurochem 59: 1459–1466
Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van Laarhoven JH, Busard HL (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial [see comments]. Br J Psychiatry 163: 451–5
Hansson LO, Waters N, Winblad B, Gottfries CG, Carlsson A (1994) Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue. J Neural Transm [Gen Sect] 98: 217–35
Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277: 968–81
Leysen JE (1990) Gaps and peculiarities in 5-HT2 receptor studies. Neuropsychopharmacol 3: 361–69
Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27: 600–11
Martin P, Waters N, Holm S, Carlsson A, Carlsson ML (1995) The stimulation of forward locomotion by MK-801 is abolished by low doses of the 5-HT2a antagonist MDL 100,907. 25th Annual Meeting, Society for Neuroscience, 21, part 3, p 2057
Middlemiss DN, Tricklebank MD (1992) Centrally active 5-HT receptor agonists and antagonists. Neurosci Biobehav Rev 16: 75–82
Shi WX, Nathaniel P, Bunney BS (1995) Ritanserin, a 5-HT2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons. J Pharmacol Exp Ther 274: 735–40
Van Wijngaarden I, Tulp MT, Soudijn W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 188: 301–12
Waters N, Carlsson A, Hansson L (1994) An animal model of schizophrenia based on multivariate analysis monoaminergic biochemistry and behaviour 24th Annual Meeting, Society for Neuroscience, 20, part 1, p 825
Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83: 7104–8
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martin, P., Waters, N., Carlsson, A. et al. The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J. Neural Transmission 104, 561–564 (1997). https://doi.org/10.1007/BF01277672
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01277672